Androgen deprivation therapy for two years after radiation therapy improves disease-free survival in patients with advanced prostate cancer
Study analyzes 15-year follow-up of RTOG 9202A long-term follow-up of RTOG 9202 (Hanks 2004) indicates that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen deprivation (LTAD) therapy after radiation therapy (RT) plus short- term androgen deprivation (STAD) therapy improved disease-free survival (DFS) by 60 percent compared to patients who only received RT plus STAD, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Men with advanced prostate cancer typically receive